The Novo Nordisk Foundation of Basic Metabolic Health, Section for Metabolic Genetics
Copenhagen, 2100, Denmark
NCT Number: NCT01719913
Objective: To identify how specific changes of the gluten content in the diet affect the host-gut microbiome interactions with implications for metabolic health.
Design: A randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. A total number of 60 participants will be included.
Intervention: low vs high gluten intake.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Copenhagen, 2100, Denmark
The study is designed as a randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. A total number of 60 participants will be included. Participants consume, in randomized order, a gluten-poor diet (<5 g/d) in the active treatment period and a gluten-rich diet (>25 g/d) during the control period.
Measurements: Altered quantitative metagenomics at bacterial gene- and species levels is the primary outcome of this study. Secondary outcomes include metabolic and inflammatory markers, circulating appetite hormone levels,serum metabolomics, gastrointestinal transit time and intestinal permeability. Furthermore, selected control measures are included; 4-day food records and a study intervention dietary records.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
, compulsory:
Inclusion criteria
, minimum one of the following:
Exclusion criteria
Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
Time frame: Up to 3 years.
Feces samples are collected according to standard operation procedures for subsequent standardized microbial DNA extraction. Microbial DNA will be subjected to sequencing, microbial gene analyses, taxonomy analyses including enterotypes known species and unknown meta-species and functional annotation.
Time frame: Up to 2 years.
Participants are instructed in swallowing capsules containing different small non-invasive and non-absorbable plastic pellets for 6 consecutive days. On the seventh day they are having an X-ray of the abdomen taken.
Time frame: Up to 2 years.
Lactulose/mannitol ratio in urine after four hours collection following oral intake of lactulose and mannitol.
Time frame: Up to 2 years.
Breath hydrogen after intake of standardized breakfast (30,60,90,120,180 minutes)
Time frame: Up to 1 year.
Systolic and diastolic blood pressure and heart beat rate are measured after 10 min of rest according to current standard operational procedure with an automatic blood pressure meter. Participants are instructed not to talk during the measurements.
Time frame: Up to 2 years.
Saliva is collected after the participants have taken a small piece of paraffin in their mouth and have chewed until the paraffin has turned into one coherent mass (approximately one minute). Participants are swallowing the produced saliva for that minute. After this, and for the next 3 minutes, saliva is collected in a cup and handed over to the study personnel. Saliva is stored at minus 80 degrees for later studies of saliva microbial flora and saliva biochemistry.
Time frame: Up to 3 years.
Nasal fluid is collected by a non-invasive methodology for in vivo measurement of an array of immunological signalling molecules in the nasal airway lining. The method is based on a standardized collection of mucosal airway fluid from both nostrils onto small sheets of filter papers with efficient absorption properties. The technique is highly reproducible, and used for measuring immunological mediators representing the immediate response ability of the mucosal immune system.
Time frame: Up to 3 years.
Glucagon like peptide 1 and 2, Gastric inhibitory polypeptide, peptide YY and Ghrelin.
Time frame: Up to 1 year.
Levels of gliadin and Immunoglobulin A and G transglutaminase.
Time frame: Up to 2 years.
Low density Lipoproteins, High density lipoproteins, Total Cholesterol, Very low density lipoproteins and Free fatty acids.
Time frame: Up to 1 year.
Body composition (lean body mass and fat mass) is measured by bio-electrical impedance using multi frequency Quadscan.
Time frame: Up to 2 years.
Breath hydrogen measurements are done before the intake of the standardized breakfast (at 30, 60, 90, 120, 180 minutes), as an indicator of colonic fermentation.
Time frame: Up to 2 years.
Fasting insulin and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal.
Time frame: Up to 2 years.
Fasting glucose and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal.
Time frame: Up to 2 years.
Fasting.
Time frame: Up to 3 years.
High sensitive C-reactive protein, Interleukin 1, 6 and 10, Lipopolysaccharide- binding protein, Tumor necrosis factor - alfa.
Time frame: Up to 1 year.
Weight, height, sagittal height and waist circumference.
Time frame: Up to 2 years.
Validated method for dietary registration, based on 2 week and 2 weekend days.
Time frame: Up to 2 years.
Changes from baseline to after intervention in individual gastrointestinal symptoms by validated VAS-questionary.
University of Copenhagen
Other
Gut, Grain and Greens (3G): The Effect of Gluten on Gut Microbiome and Metabolic Health.
Acronym: 3G
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716579
Brain Diseases, Brain Neoplasms
Ljubljana, Slovenia
View Trial DetailsNCT07646015
Diabetes Mellitus, Diabetes Mellitus, Type 2
Mysore, Karnataka, India
View Trial DetailsNCT06017986
Metabolic Diseases, Nutritional and Metabolic Diseases
Roanoke, Virginia, United States
View Trial DetailsNCT04958109
Metabolic Diseases, Nutritional and Metabolic Diseases
Boston, Massachusetts, United States
View Trial Details